Metastatic Melanoma
Phase II study of talabostat in stage IV melanoma complete; results promising
Published in Drug Week, December 16th, 2005
These results were presented in a poster session at the International Society for Biological Therapy of Cancer meeting in Alexandria, Virginia. The company's metastatic melanoma clinical program also includes studying talabostat in a phase II trial in combination with cisplatin.
The single-agent trial included 42 patients with metastatic melanoma, 31 of whom are evaluable for response. Two patients had a response to talabostat as defined by Recist (a 30% or greater...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
Source: Drug Week (2005-12-16)
More Articles from Drug Week
- Diagnostics
Adding a bile acid sequestrant to statin therapy reported to reduce median hs-CRP levels - Drug Development
New drug application submitted for Toprol-XL and thiazide combination tablets for hypertension - Drug Development
U.S. FDA accepts supplemental application for Tysabri in multiple sclerosis - HIV/AIDS Therapy
U.S. FDA grants approval for new Kaletra tablet formulation for HIV patients - Pancreatic Cancer
Favorable 2-year survival data from phase II clinical trial of GVAX vaccine for pancreatic cancer - Acute Coronary Syndrome
AZD6140 plus aspirin assessed for safety, tolerability as antiplatelet therapy - More from this issue of Drug Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
